Global Blood Therapeutics, Inc.
GBTDelisted Oct 5, 2022- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001629137
Global Blood Therapeutics, Inc. was delisted on Oct 5, 2022; its insiders filed their last Form 4 on Oct 6, 2022; 247 institutions reported holding it in 13F filings for Q3 2022, worth $4.67B in total; Soros Fund Management was the only superinvestor holding it.
Q3 2022 vs. Q2 2022
How the institutions holding Global Blood Therapeutics, Inc. changed between Q2 2022 and Q3 2022.
All holders in Q3 2022All holders in Q2 2022
| Measure | Q2 2022 | Of which not filed for Q3 2022 | Q3 2022 | Change |
|---|---|---|---|---|
| Holders | 195 | 1 | 247 | +53 |
| Shares | 71.5M | 27.9K | 68.6M | −2.91M (−4.1%) |
| Value | $2.29B | $892.0K | $4.67B | +$2.39B (+104.5%) |
1 institution that held it in Q2 2022 haven't filed for Q3 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (114)
Institutions that held Global Blood Therapeutics, Inc. at the end of Q3 2022 but not at the end of Q2 2022.
Showing the largest 100 of 114 by value.
Sold out (61)
Institutions that held Global Blood Therapeutics, Inc. at the end of Q2 2022 and filed for Q3 2022 without it.
Not filed for Q3 2022 yet (1)
Institutions that held Global Blood Therapeutics, Inc. at the end of Q2 2022 and haven't filed a 13F for Q3 2022. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2022 | Value, Q2 2022 |
|---|---|---|
| Taylor Wealth Management Partners | 27,917 | $892.0K |